20/20 Biolabs, Inc. last reported quarterly results on Aug 17, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $730,571 and diluted EPS of -$0.26. It usually reports 1–48 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 17, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Tuesday. Based on how many days after a quarter ends the company has reported recently. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 1–48 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 17, 2026
48 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
1
|
-2
|
-0.26
|
|
Apr 1, 2026
1 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
0
|
-2
|
-0.28
|
Company profile
- Industry
- Services-Testing Laboratories (SIC 8734)
- Listed as
- AIDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Rockville, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1139685
- Former names
- 20/20 GeneSystems, Inc. (until Feb 26, 2025); 20/20 GENE SYSTEMS INC (until Apr 28, 2004)
Other Services-Testing Laboratories companies
- UL Solutions Inc. ULS
- Neogenomics Inc NEO
- Hypha Labs, Inc. FUNI
Source: SEC EDGAR filings. This is company-reported data, not investment advice.